Patents Assigned to Huashan Hospital, Fudan University
  • Publication number: 20240428955
    Abstract: A method and a system of molecular typing and subtyping classifier for immune-related diseases are provided. The method includes: conducting molecular typing via a clustering algorithm in a training set to obtain a plurality of subtypes stably appearing in the training set and a marker gene for each subtype; conducting enrichment analysis on marker genes for the plurality of subtypes, conducting immune cell infiltration evaluation on the plurality of subtypes, and dividing the plurality of subtypes into a plurality of subtype classes according to results of the analysis and the evaluation; comparing treatment response rates of different subtype classes through a comparison set to determine a subtype class to be identified; constructing a support vector machine model with feature genes screened and an optimal parameter combination; and determining whether immune-related disease data to be classified is the subtype class to be identified.
    Type: Application
    Filed: August 12, 2022
    Publication date: December 26, 2024
    Applicant: HUASHAN HOSPITAL, FUDAN UNIVERSITY
    Inventors: Jie LIU, Feifei LUO, Shaocong MO, Huan SONG
  • Publication number: 20230193256
    Abstract: A system and method for gene editing by using an engineered cell are provided. The system includes the engineered cell embedded with a synthetic protein receptor and a target cell. The engineered cell contains a CRISPR/CasRx system and a sgRNA gene sequence. The synthetic protein receptor includes an extracellular target cell recognition domain, a native Notch core domain, an intramembranous hydrolyzable polypeptide and effectors. The extracellular target cell recognition domain can recognize antigen molecules on the target cell surface; and the effectors act as transcription factors for CasRx enzyme and sgRNAs. CasRx and gRNA are expressed in the engineered cell for gene editing to edit mRNA of the target cell. In this way, the application range of the engineered cell is expanded, the pertinence and specificity of gene editing are improved, the off-target effect is reduced, the collective non-specific reaction is reduced, and the safety of gene editing is improved.
    Type: Application
    Filed: August 22, 2022
    Publication date: June 22, 2023
    Applicants: Huashan Hospital, Fudan University
    Inventors: Jianhong ZHU, Tianwen LI, Kezhu CHEN